Meitheal Pharmaceuticals, Inc., a fully integrated generic injectables company headquartered in Chicago, has expanded its portfolio of generic injectable products through an asset purchase agreement made by its parent company, Hong Kong King-Friend Industry Co., (HKF). This agreement has increased Meitheal's total portfolio of generic injectables to include 82 products.

Tom Shea, CEO of Meitheal, expressed his excitement about this acquisition, highlighting its significance in enhancing their innovative portfolio and reinforcing their commitment to making life-changing medicines more accessible through global partnerships. This strategic move aligns with their mission to provide healthcare solutions that meet the evolving needs of both patients and healthcare providers.

Under the terms of the agreement, HKF will acquire the rights, title, and interest in 18 additional generic injectable products within the United States. HKF will be responsible for the ongoing development and manufacturing of these products and will grant Meitheal exclusive rights to commercialize them in the U.S.

Eric Tang, President of HKF, expressed their pleasure in securing the rights to this extensive portfolio of generic injectables. They are confident in Meitheal's capabilities to bring these products to the U.S. market and look forward to advancing their development to provide essential options to patients in need.